The Thai Journal of Pharmaceutical Sciences
Abstract
Polycystic ovarian syndrome (PCOS) is a common endocrine syndrome in women associated with many other complications such as insulin resistance, obesity, hirsutism, increased risk of cardiovascular diseases, and infertility. As the pathophysiology of the syndrome still is not clear, it is difficult for the health-care professionals to precisely treat the syndrome. The cause of this syndrome is also unknown, but the evidences suggest that the factors such as environment, diet, and lifestyle are also a very common cause now a day for the syndrome. Recent pathophysiology of PCOS based on the Anti-Mullerian Hormone (AMH) and melatonin levels has been seen and discussed in the review. AMH has been marked as a biomarker of ovarian function and infertility. It appears to relate with the levels of androgens in the pathophysiology of ovarian function in PCOS. On the other hand, melatonin levels have been in the pathophysiology of PCOS due to the affect in circadian cycle in the women due to the occupational stress and night shifts in many professions. The treatment of PCOS is not complicated but always need long-term clinical management for the women. The review also discusses about the novel therapeutic targets for the treatment of PCOS such as melatonin treatment, apelin receptor, and miRNAs which can be obliging with the future perspectives.
DOI
10.56808/3027-7922.2632
First Page
481
Last Page
489
Recommended Citation
Begum, Rukaiah Fatma; Sumithra, M.; Chitra, V.; and Devi, Sharmila
(2022)
"Insights into Novel Therapeutic Targets and Molecular Aspects in Polycystic Ovarian Syndrome: A Review,"
The Thai Journal of Pharmaceutical Sciences: Vol. 46:
Iss.
5, Article 1.
DOI: https://doi.org/10.56808/3027-7922.2632
Available at:
https://digital.car.chula.ac.th/tjps/vol46/iss5/1